1083197-78-7

Basic information

• Product Name: 4-(Trifluoromethyl)-3-formylpyridine
• Synonyms: 4-(TRIFLUOROMETHYL)NICOTINALDEHYDE;4-TRIFLUOROMETHYL-3-FORMYLPYRIDINE;4-Trifluoromethyl-3-pyridine carbaldehyde;4-Trifluoromethyl-pyridine-3-carbaldehyde
• CAS NO: 1083197-78-7
• Molecular Formula: C₇H₄F₃NO
• Molecular Weight: 175
• Mol File: 1083197-78-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(Trifluoromethyl)-3-formylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Trifluoromethyl)-3-formylpyridine(1083197-78-7)
• EPA Substance Registry System: 4-(Trifluoromethyl)-3-formylpyridine(1083197-78-7)

Safety Data

• Hazardous Substances Data: 1083197-78-7(Hazardous Substances Data)

Usage

General Description

4-(Trifluoromethyl)-3-formylpyridine is a specialized chemical compound that belongs to the family of pyridines, which are aromatic chemical compounds and contain nitrogen. Characterized by its robust structure, it has a trifluoromethyl functional group, indicating the presence of three fluorine atoms. 4-(Trifluoromethyl)-3-formylpyridine is mainly used in the field of synthetic chemistry, specifically in the synthesis of other complex compounds and potentially for developing pharmacologically active substances. Its exact properties, handling, and safety measures would depend on its particular synthesis and specific use.

Upstream product

• 936841-70-2 3-bromo-4-(trifluoromethyl)pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 323180-94-5 N-methoxy-N-methyl-4-(trifluoromethyl)nicotinamide 
• 158063-66-2 4-(trifluoromethyl)nicotinic acid 

Downstream Products

• 198401-76-2 (4-(trifluoromethyl)pyridin-3-yl)methanol 

Relevant articles and documents

Discovery of TRPM8 Antagonist (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine

Transient-receptor-potential melastatin 8 (TRPM8), the predominant mammalian cold-temperature thermosensor, is a nonselective cation channel expressed in a subpopulation of sensory neurons in the peripheral nervous system, including nerve circuitry implicated in migraine pathogenesis: the trigeminal and pterygopalatine ganglia. Genomewide association studies have identified an association between TRPM8 and reduced risk of migraine. This disclosure focuses on medicinal-chemistry efforts to improve the druglike properties of initial leads, particularly removal of CYP3A4-induction liability and improvement of pharmacokinetic properties. A novel series of biarylmethanamide TRPM8 antagonists was developed, and a subset of leads were evaluated in preclinical toxicology studies to identify a clinical candidate with an acceptable preclinical safety profile leading to clinical candidate AMG 333, a potent and highly selective antagonist of TRPM8 that was evaluated in human clinical trials.

TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS

Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula (I) have a structure where the definitions of the variables are provided herein.